Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Precision Cell Immunotherapy (Ningbo Cancer Hospital)
- Development stage
- Unknown
- Lead developer
- Ningbo Cancer Hospital
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Subcutaneous, Intravenous
01
Overview
Precision Cell Immunotherapy is an autologous cell-based therapeutic regimen developed by Ningbo Cancer Hospital for the treatment of advanced lung cancer. The therapy utilizes a dual-component approach consisting of autologous dendritic cells (DC) and Precision Natural Autologous T cells (PNAT). Dendritic cells are administered subcutaneously to act as professional antigen-presenting cells, stimulating the patient's immune system to recognize and respond to tumor-specific antigens. The PNAT component, which likely consists of expanded autologous effector T cells or natural killer cells, is administered intravenously to provide direct cytotoxic activity against cancer cells. In clinical trials, this immunotherapy is typically evaluated in combination with standard-of-care chemotherapy, such as cisplatin and gemcitabine, to leverage potential synergistic effects between immune activation and direct cytotoxic drug action.
- Other names
- Precision CellsDC+PNAT cell therapy
02
Targets
Neoantigen-specific T-cell receptor
Beyond the preview
Go deeper on Precision Cell Immunotherapy (Ningbo Cancer Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Precision Cell Immunotherapy (Ningbo Cancer Hospital).